Thalidomide to Chemotherapy Related Nausea and Vomiting in Pancreatic Cancer
Trial statusRecruiting
Trial phasePhase 3
Trial typeInterventional
Biological sexAll
Age18-80
SponsorFudan University
About this trial
The purpose of this study is to evaluate the efficacy of thalidomide on improving the quality of life for metastatic pancreatic cancer patients receiving gemcitabine and nab-paclitaxel chemotherapy.
Eligibility criteria
Qualifiers
Ability to understand and the willingness to sign a written informed consent document.
Age ≥ 18 years and ≤ 80 years.
Eastern Cooperative Oncology Group (ECOG) performance status 0-2.
Histologically or cytologically confirmed metastatic pancreas adenocarcinoma.
Disqualifiers
Patients who have received any form of anti-tumor therapy.
The diagnosis was confirmed by pathology as non-adenocarcinoma of pancreas.
Inflammation of the digestive tract, including pancreatitis, cholecystitis, cholangitis, etc.
Pregnant or nursing women.
Trial design
Treatments tested in this trial
- Thalidomide
- Nab paclitaxel
- Gemcitabine
- Placebo
Treatment groups
100 Participants
are divided into 2 treatment groupsLocations
1Shanghai Cancer Center200032, ShanghaiShanghai Municipality, China
Sponsors and collaborators
Fudan University
Lead sponsor
Source ClinicalTrials.gov